BackBristol-Myers Squibb Overview

Bristol-Myers Squibb Receivables

Track Bristol-Myers Squibb's receivables ($11B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$10.55B

Peer trimmed avg / median

Loading

Bristol-Myers Squibb Receivables History

Loading

Bristol-Myers Squibb vs. peers: Receivables Comparison

Loading

Bristol-Myers Squibb Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bristol-Myers Squibb (BMY) FAQ

As of the most recent data (June 2026), BMY shows a receivables of $11B. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BMY's receivables is now $11B (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Bristol-Myers Squibb is outperforming or lagging.

Tracking BMY's receivables over time shows whether Bristol-Myers Squibb is scaling, shrinking, or reshaping that part of the business. The current reading is $11B In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Bristol-Myers Squibb's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $11B) with ownership activity and broader fundamentals.

Bristol-Myers Squibb's receivables is $11B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.